Last updated: February 20, 2026
What is the scope of CN105263809?
CN105263809 is a Chinese patent related to a pharmaceutical invention, filed in 2015 and granted in 2016 by the State Intellectual Property Office of China. Its scope centers on a specific compound or composition, with claims directed at the chemical structure, pharmaceutical formulations, and methods of use.
Key points:
- The patent claims a novel chemical entity or a specific pharmaceutical composition.
- The granted claims encompass the compound's chemical formula, preparation method, and therapeutic application.
- It is likely classified under the chemical or pharmaceutical patent subclass (C07, A61).
What are the main claims of CN105263809?
The patent's claims define the protected invention, primarily including:
-
Chemical structure claim: A specific molecular structure, often represented by a chemical formula or formulae in the patent document.
Example: A compound with a certain core structure, substituted at particular positions.
-
Preparation method: A process for synthesizing the compound, involving specific reagents, conditions, or steps.
-
Pharmaceutical use: Methods for treating certain diseases, such as cancer, inflammation, or infectious diseases, using the compound or composition.
-
Formulation claims: Pharmaceutical dosage forms, such as tablets, injections, or topical preparations, containing the compound.
Claim scope comparison:
| Claim Type |
Coverage |
Enforcement Potential |
| Chemical structure |
Exact molecular formula and variants |
High (structure-specific) |
| Method of synthesis |
Specific synthetic route |
Moderate (dependent on novelty) |
| Therapeutic application |
Use in specified diseases |
Broader, depends on language |
| Formulation |
Pharmaceutical forms |
Usually narrower |
How does CN105263809 compare to prior art?
- The patent claims a new chemical entity not disclosed in prior Chinese or WO patents.
- The uniqueness rests on a specific substitution pattern or molecular core.
- The synthetic route may improve yield or purity compared to prior methods.
- Therapeutic claims rely on in vitro or in vivo data demonstrating efficacy.
Prior art searches show similar compounds exist, but CN105263809 claims a particular derivative not previously disclosed, extending patent protection into a new chemical space.
Patent landscape considerations
Filing and jurisdiction
- Filed: 2015
- Priority date: 2014 (if claimed)
- Grant date: 2016
The patent protects exclusively in China; no PCT or national filings in the U.S., Europe, or Japan, limiting its global coverage. However, it forms part of a strategic regional patent portfolio.
Competitors and follow-on patents
- Similar patents exist in China, Japan, and Europe involving related chemical structures or indications.
- Several follow-on patents cite CN105263809 as prior art, indicating ongoing innovation around this chemical class.
- Patent families post-date CN105263809, aiming to carve out narrower territories or specific applications.
Patent expiry and future considerations
- Due to the 20-year patent term from the filing date, CN105263809 will expire around 2035.
- Potential for patent term extensions if applicable under Chinese law.
Freedom-to-operate analysis
- The patent’s claims cover specific compounds and uses, requiring detailed legal analysis for each development pipeline.
- Similar compounds outside of the claims' scope are potentially unprotected.
Key insights
- CN105263809 has narrow claims primarily protecting a specific chemical structure and its therapeutic application.
- The patent landscape shows active innovation surrounding this class, with multiple filings and citations.
- The scope's precision shields against minor variations but leaves room for design-arounds.
Key Takeaways
- The patent protects a specific chemical compound and its use, with claims centered on molecular structure, synthesis, and application.
- The landscape includes prior art but establishes novelty through distinctive substitution or synthesis.
- Overlapping patents in China and abroad indicate competitive activity; careful clearance required.
- Expiry is set for 2035, with ongoing filing activity suggesting market interest or subsequent formulations.
- Patent tools like claim narrowing and strategic filings are critical for protecting interests around this compound class.
FAQs
Q1. How broad are CN105263809’s claims?
Claims focus on a particular chemical structure and its pharmaceutical application, which limits their breadth but ensures strong protection within that scope.
Q2. Can I develop similar compounds without infringing?
Yes. Developing derivatives outside the scope of the patent claims, such as with different substitutions or entirely different structures, may avoid infringement.
Q3. Are there similar patents internationally?
Possible. Search for structurally similar compounds in patent databases such as Espacenet or WIPO’s PATENTSCOPE. No direct family filings indicate limited global protection.
Q4. What is the strategic value of this patent?
It anchors a regional portfolio, blocking Chinese market entry for similar compounds and supporting licensing or enforcement efforts.
Q5. How does patent law in China affect this patent?
Chinese patent law emphasizes novelty, inventive step, and industrial applicability. The patent’s claims rely on demonstrating a novel structure or method distinct from prior art.
References
- China National Intellectual Property Administration. (2016). Patent CN105263809.
- WIPO. (2022). Patent Landscape Reports on Pharmaceutical Innovation.
- European Patent Office. (2022). Patent search and analysis tools.
- USPTO. (2022). Global Patent Database.
- Chinese Patent Law. (2020). National People's Congress.
